Effect of Preoperative Recombinant Human Erythropoietin on Transfusion Risk in Valaulr Heart Surgery

This study is currently recruiting participants.

Verified by Yonsei University, July 2009

First Received: July 14, 2009 No Changes Posted

Sponsored by:	Yonsei University
Information provided by:	Yonsei University
ClinicalTrials.gov Identifier:	NCT00939978

Purpose

The administration of rhEPO on the one day before cardiac surgery will be effective to decrease the bleeding due to the surgery.

Condition	Intervention
Cardiac Surgery	Drug: rhEPO

Study Type:

Interventional

Resource links provided by NLM:

MedlinePlus related topics: Heart Surgery Surgery

Further study details as provided by Yonsei University:

Arms	Assigned Interventions
control group: Placebo Comparator	Drug: rhEPO

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Uncontrolled hypertension(diastolic blood pressure(DBP)>100 mmHg), Hct > 45%, Plt. count)>450,000, there are no history in seizure, thrombus, cancer, acute hepatitis, alcoholism, peripheral blood vessel disease, pure red blood cell dysfunction, liver function failure, chronic multiple arthritis.

No pregnancy, acute hyper parathyroidism.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00939978

Contacts

Contact: Young Lan Kwak, MD, PhD

82-2-2228-8513

Locations

Korea, Republic of
Severance hospital	Recruiting
Seoul, Korea, Republic of, 120-752
Contact: Young Lan Kwak Kwak, MD 82-2-2228-8513 ylkwak@yuhs.ac

Sponsors and Collaborators

Yonsei University

More Information

No publications provided

Study ID Numbers:	4-2008-0427
Study First Received:	July 14, 2009
Last Updated:	July 14, 2009
ClinicalTrials.gov Identifier:	NCT00939978 History of Changes
Health Authority:	South Korea: Food and Drug Administration

Study placed in the following topic categories:

Epoetin Alfa

ClinicalTrials.gov processed this record on September 11, 2009